Combination therapy reduced HER2-positive breast cancers

Bookmark and Share
Sorry, this item is currently unavailable.
Published: 18 Jan 2011
Views: 6333
Prof José Baselga - Massachusetts General Hospital Cancer Center, USA
A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2- positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12 2010.